Jay Olson
Stock Analyst at Oppenheimer
(4.16)
# 447
Out of 5,127 analysts
248
Total ratings
45.23%
Success rate
16.59%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Perform | $21 → $23 | $23.22 | -0.95% | 16 | Feb 6, 2026 | |
| BIIB Biogen | Maintains: Outperform | $205 → $225 | $193.81 | +16.09% | 26 | Jan 30, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $75 → $150 | $96.74 | +55.05% | 10 | Jan 27, 2026 | |
| CHRS Coherus Oncology | Initiates: Outperform | $10 | $2.06 | +385.44% | 1 | Jan 22, 2026 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $250 → $750 | $319.54 | +134.71% | 3 | Dec 15, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $28 → $58 | $37.98 | +52.71% | 4 | Dec 9, 2025 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $600 → $650 | $488.26 | +33.13% | 12 | Nov 20, 2025 | |
| IBIO iBio, Inc. | Initiates: Outperform | $5 | $2.41 | +107.47% | 1 | Oct 21, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Outperform | $84 → $90 | $84.79 | +6.14% | 4 | Oct 8, 2025 | |
| IMRX Immuneering | Maintains: Outperform | $21 → $30 | $4.95 | +506.06% | 3 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $44 | $5.78 | +661.25% | 4 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $14 | $3.94 | +255.78% | 1 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $8.86 | - | 15 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $65 | $3.79 | +1,615.04% | 1 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $65 | $1.36 | +4,679.41% | 5 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $13 | $1.69 | +669.23% | 3 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $90 | $37.07 | +142.78% | 6 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $42 | $20.84 | +101.54% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $41 → $33 | $43.95 | -24.91% | 6 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $40 | $12.49 | +220.26% | 9 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $20 | $4.18 | +378.47% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $5.45 | +450.46% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $82 | $109.03 | -24.79% | 14 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $10 | $24.00 | -58.33% | 4 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $138 | $29.30 | +370.99% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $1.79 | +346.93% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $375.82 | +1.11% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $139.56 | +56.92% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $1.81 | +562.98% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $3.71 | +385.18% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 | $13.98 | +615.31% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $49.70 | +91.15% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $0.78 | +3,116.26% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $1.08 | +733.33% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,200 → $500 | $1.16 | +43,003.45% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $13.83 | +51.84% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.20 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $17.99 | +366.93% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $2.48 | - | 3 | Jul 11, 2017 |
ACADIA Pharmaceuticals
Feb 6, 2026
Maintains: Perform
Price Target: $21 → $23
Current: $23.22
Upside: -0.95%
Biogen
Jan 30, 2026
Maintains: Outperform
Price Target: $205 → $225
Current: $193.81
Upside: +16.09%
Revolution Medicines
Jan 27, 2026
Maintains: Outperform
Price Target: $75 → $150
Current: $96.74
Upside: +55.05%
Coherus Oncology
Jan 22, 2026
Initiates: Outperform
Price Target: $10
Current: $2.06
Upside: +385.44%
Praxis Precision Medicines
Dec 15, 2025
Maintains: Outperform
Price Target: $250 → $750
Current: $319.54
Upside: +134.71%
Terns Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $28 → $58
Current: $37.98
Upside: +52.71%
Madrigal Pharmaceuticals
Nov 20, 2025
Maintains: Outperform
Price Target: $600 → $650
Current: $488.26
Upside: +33.13%
iBio, Inc.
Oct 21, 2025
Initiates: Outperform
Price Target: $5
Current: $2.41
Upside: +107.47%
Ionis Pharmaceuticals
Oct 8, 2025
Maintains: Outperform
Price Target: $84 → $90
Current: $84.79
Upside: +6.14%
Immuneering
Sep 25, 2025
Maintains: Outperform
Price Target: $21 → $30
Current: $4.95
Upside: +506.06%
Aug 11, 2025
Maintains: Outperform
Price Target: $48 → $44
Current: $5.78
Upside: +661.25%
Jul 29, 2025
Initiates: Outperform
Price Target: $14
Current: $3.94
Upside: +255.78%
May 27, 2025
Downgrades: Perform
Price Target: n/a
Current: $8.86
Upside: -
May 21, 2025
Initiates: Outperform
Price Target: $65
Current: $3.79
Upside: +1,615.04%
May 15, 2025
Maintains: Outperform
Price Target: $80 → $65
Current: $1.36
Upside: +4,679.41%
May 14, 2025
Maintains: Outperform
Price Target: $15 → $13
Current: $1.69
Upside: +669.23%
Mar 14, 2025
Upgrades: Outperform
Price Target: $90
Current: $37.07
Upside: +142.78%
Mar 3, 2025
Maintains: Outperform
Price Target: $50 → $42
Current: $20.84
Upside: +101.54%
Jan 24, 2025
Downgrades: Perform
Price Target: $41 → $33
Current: $43.95
Upside: -24.91%
Jan 13, 2025
Maintains: Outperform
Price Target: $60 → $40
Current: $12.49
Upside: +220.26%
Dec 11, 2024
Maintains: Outperform
Price Target: $80 → $20
Current: $4.18
Upside: +378.47%
Dec 6, 2024
Initiates: Outperform
Price Target: $30
Current: $5.45
Upside: +450.46%
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $109.03
Upside: -24.79%
Oct 17, 2024
Maintains: Outperform
Price Target: $9 → $10
Current: $24.00
Upside: -58.33%
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $29.30
Upside: +370.99%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $1.79
Upside: +346.93%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $375.82
Upside: +1.11%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $139.56
Upside: +56.92%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $1.81
Upside: +562.98%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $3.71
Upside: +385.18%
May 15, 2024
Maintains: Outperform
Price Target: $100
Current: $13.98
Upside: +615.31%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $49.70
Upside: +91.15%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $0.78
Upside: +3,116.26%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $1.08
Upside: +733.33%
Nov 30, 2023
Maintains: Outperform
Price Target: $1,200 → $500
Current: $1.16
Upside: +43,003.45%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $13.83
Upside: +51.84%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $4.20
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $17.99
Upside: +366.93%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $2.48
Upside: -